NLO is one of the largest and most prominent pharma, medtech, biotech and life sciences Intellectual Property consultancies in Europe. The teams not only accelerate in their core aim to protect and defend patent portfolios that fit the business strategy and that are aligned with the preclinical and clinical development programs. In addition, the pharma patent attorneys expose it as their natural habit to be acquainted with the full breadth of the drug development trajectory. Starting with a preliminary idea and some data, often in the academic or hospital context, progressing to a spin-out company or out-licensing, moving forward to first-in-human trials, up to market authorization, pricing- and reimbursement establishment and post-marketing surveillance: just to name a few of the aspects in which the pharma team gets co-involved together with the inventors, regulatory experts, clinicians, health economics experts, investors, patient advocacy groups, etc., etc. It is this anchoring in the many aspects of the drug development field that is highly valued by the TTO’s, researchers, pharma companies, investors.

NLO has entered into a strategic partnership with Ipsilon, a leading full-service IP firm headquartered in Paris. This marks an exciting step forward in the ambition to be the go-to IP partner for pharma & life sciences innovators worldwide.